Armstrong, A.W., Papp, K.A., Zhuo, J., Becker, B., Zhong, Y., Beaumont, J.L., DeRosa, M., Kisa, R.M., Banerjee, S. and Strober, B. 2022. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s63. DOI:https://doi.org/10.25251/skin.6.supp.63.